Last Name

Jessie Ng, PhD, MS

TitleResearch Faculty PhD
InstitutionChildren's Mercy Kansas City
Address2401 Gillham Rd
Kansas City MO 64108
vCardDownload vCard
    Other Positions
    TitleAssistant Professor of Pediatrics
    InstitutionUniversity of Missouri-Kansas City

    TitleResearch Assistant Professor of Cancer Biology
    InstitutionUniversity of Kansas Medical Center
    DepartmentCancer Biology

    Collapse Biography 
    Collapse education and training
    St Jude Children’s Research Hospital, Memphis, TN, USAFellowshipDevelopmental Neurobiology
    Erasmus Medical Center, Erasmus University of Rotterdam, Rotterdam, The NetherlandsFellowshipCell Biology and Genetics
    Erasmus Medical Center Erasmus University of Rotterdam, Rotterdam, The NetherlandsPhDCell Biology and Genetics
    Leiden University, Leiden, The NetherlandsMSMedical Biology, Molecular Cell Biology, and Molecular Genetics & Developmental Genetics
    Institute of Higher Professional Education of Engineering & Technology, Delft & Rotterdam, The NetherlandsBSMedical Biotechnology and Clinical Genetics
    Collapse awards and honors
    2004 - 2006LIMA International Award for Excellence in Pediatric Brain Tumor Research, Children Brain Tumor Foundation (CBTF)
    2008Most outstanding presentation in the clinical/translational track, The Children’s Hospital of Philadelphia
    2008Scholar-in-Training Award, American Association for Cancer Research (AACR)
    2008AACR-WICR Brigid G. Leventhal Scholar in Cancer Research Award, American Association for Cancer Research (AACR)

    Collapse Overview 

    Collapse Research 
    Collapse research overview
    Dr. Jessie Ng is working to develop better treatments for the aggressive brain tumors medulloblastoma (MB) and atypical teratoid rhabdoid tumor (AT/RT). Over the past several years, Dr. Ng and coworkers in Dr. Curran’s lab helped develop a new approach to the treatment of MB using Hedgehog (Hh) pathway inhibitors. The lab conducted molecular gene expression studies that identified four major subtypes of MB tumors and developed a mouse model (Ptc1/p53) for high-incidence, early-onset Hh subtype MB. Using this spontaneous central nervous system (CNS) mouse model, they demonstrated that oral delivery of small molecule inhibitors of Smoothened (Smo), called GDC-0449 or vismodegib, eliminated even large spontaneous brain tumors in mice. They worked with Curis Inc., and later Genentech Inc., to demonstrate proof-of-concept of the use of Hh inhibitors in cancer. This work led to successful Phase I and II clinical trials of Smo inhibitors in pediatric and adult MB that recapitulated all the major findings obtained in mice. Because of these efforts, the first Smo inhibitor (vismodegib) was approved for treatment of advanced basal cell carcinoma in 2012. The next step is to focus on targeting drug-resistant brain tumors. Dr. Ng will use in vitro high-throughput drug screening as well as noninvasive imaging approaches (such as MRI and CT), drug delivery therapies and next-generation sequencing. The ultimate goal of the research is to develop new drugs for clinical trials in pediatric brain cancer. Dr. Ng’s research is also investigating the role of INI1 (Integrase Interactor 1), also known as SNF5 or SMARCB1. SNF5 is a key component of the SWI/SNF (switch/sucrose nonfermentable) chromatin remodeling tumor suppressor complex, which is an ATP-dependent nucleosome-remodeling complex that regulates gene transcription in CNS development and tumorigenesis, including the pediatric CNS tumor AT/RT. Dr. Ng has generated the first CNS mouse model for AT/RT, which is quite crucial because with this model they can now test potential drugs in vivo and investigate the cell of origin to understand the cancer biology of AT/RT.
    Collapse research activities and funding
         (Jessie Ng)Jan 1, 2018
    Children's Mercy Hospital Midwest Cancer Alliance Partner Advisory Board Funding
    Overcoming drug resistance in Hedgehog pathway medulloblastoma
    Role Description: To identify, understand, and overcome the mechanisms responsible for resistance to Hedgehog (Smoothened) inhibitors
    Role: PI

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Du F, Yuelling L, Lee EH, Wang Y, Liao S, Cheng Y, Zhang L, Zheng C, Peri S, Cai KQ, Ng JMY, Curran T, Li P, Yang ZJ. Leukotriene Synthesis Is Critical for Medulloblastoma Progression. Clin Cancer Res. 2019 11 01; 25(21):6475-6486. PMID: 31300449.
      View in: PubMed
    2. Gordon RE, Zhang L, Peri S, Kuo YM, Du F, Egleston BL, Ng JMY, Andrews AJ, Astsaturov I, Curran T, Yang ZJ. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma. Clin Cancer Res. 2018 03 15; 24(6):1375-1388. PMID: 29437795.
      View in: PubMed
    3. Liu Y, Yuelling LW, Wang Y, Du F, Gordon RE, O'Brien JA, Ng JMY, Robins S, Lee EH, Liu H, Curran T, Yang ZJ. Astrocytes Promote Medulloblastoma Progression through Hedgehog Secretion. Cancer Res. 2017 12 01; 77(23):6692-6703. PMID: 28986380.
      View in: PubMed
    4. Li P, Lee EH, Du F, Gordon RE, Yuelling LW, Liu Y, Ng JM, Zhang H, Wu J, Korshunov A, Pfister SM, Curran T, Yang ZJ. Nestin Mediates Hedgehog Pathway Tumorigenesis. Cancer Res. 2016 09 15; 76(18):5573-83. PMID: 27496710.
      View in: PubMed
    5. Melo FM, Couto PP, Bale AE, Bastos-Rodrigues L, Passos FM, Lisboa RG, Ng JM, Curran T, Dias EP, Friedman E, De Marco L. Whole-exome identifies RXRG and TH germline variants in familial isolated prolactinoma. Cancer Genet. 2016 06; 209(6):251-7. PMID: 27245436.
      View in: PubMed
    6. Ng JM, Martinez D, Marsh ED, Zhang Z, Rappaport E, Santi M, Curran T. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53. Cancer Res. 2015 Nov 01; 75(21):4629-39. PMID: 26363008.
      View in: PubMed
    7. Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin G, Fan CM, Ng JM, Curran T, Hua X. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Res. 2013 Apr 15; 73(8):2650-8. PMID: 23580576.
      View in: PubMed
    8. Wang Y, Davidow L, Arvanites AC, Blanchard J, Lam K, Xu K, Oza V, Yoo JW, Ng JM, Curran T, Rubin LL, McMahon AP. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem Biol. 2012 Aug 24; 19(8):972-82. PMID: 22921064.
      View in: PubMed
    9. Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer. 2011 May 26; 11(7):493-501. PMID: 21614026.
      View in: PubMed
    10. Brechbiel JL, Ng JM, Curran T. PTHrP treatment fails to rescue bone defects caused by Hedgehog pathway inhibition in young mice. Toxicol Pathol. 2011 Apr; 39(3):478-85. PMID: 21411723.
      View in: PubMed
    11. Hoogstraten D, Bergink S, Ng JM, Verbiest VH, Luijsterburg MS, Geverts B, Raams A, Dinant C, Hoeijmakers JH, Vermeulen W, Houtsmuller AB. Versatile DNA damage detection by the global genome nucleotide excision repair protein XPC. J Cell Sci. 2008 Sep 01; 121(Pt 17):2850-9. PMID: 18682493.
      View in: PubMed
    12. Kimura H, Ng JM, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 2008 Mar; 13(3):249-60. PMID: 18328428.
      View in: PubMed
    13. Giglia-Mari G, Miquel C, Theil AF, Mari PO, Hoogstraten D, Ng JM, Dinant C, Hoeijmakers JH, Vermeulen W. Dynamic interaction of TTDA with TFIIH is stabilized by nucleotide excision repair in living cells. PLoS Biol. 2006 Jun; 4(6):e156. PMID: 16669699.
      View in: PubMed
    14. Okuda Y, Nishi R, Ng JM, Vermeulen W, van der Horst GT, Mori T, Hoeijmakers JH, Hanaoka F, Sugasawa K. Relative levels of the two mammalian Rad23 homologs determine composition and stability of the xeroderma pigmentosum group C protein complex. DNA Repair (Amst). 2004 Oct 05; 3(10):1285-95. PMID: 15336624.
      View in: PubMed
    15. Ng JM, Vermeulen W, van der Horst GT, Bergink S, Sugasawa K, Vrieling H, Hoeijmakers JH. A novel regulation mechanism of DNA repair by damage-induced and RAD23-dependent stabilization of xeroderma pigmentosum group C protein. Genes Dev. 2003 Jul 01; 17(13):1630-45. PMID: 12815074.
      View in: PubMed
    16. Jaspers NG, Raams A, Kelner MJ, Ng JM, Yamashita YM, Takeda S, McMorris TC, Hoeijmakers JH. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst). 2002 Dec 05; 1(12):1027-38. PMID: 12531012.
      View in: PubMed
    17. Ng JM, Vrieling H, Sugasawa K, Ooms MP, Grootegoed JA, Vreeburg JT, Visser P, Beems RB, Gorgels TG, Hanaoka F, Hoeijmakers JH, van der Horst GT. Developmental defects and male sterility in mice lacking the ubiquitin-like DNA repair gene mHR23B. Mol Cell Biol. 2002 Feb; 22(4):1233-45. PMID: 11809813.
      View in: PubMed
    18. Neuteboom LW, Ng JM, Kuyper M, Clijdesdale OR, Hooykaas PJ, van der Zaal BJ. Isolation and characterization of cDNA clones corresponding with mRNAs that accumulate during auxin-induced lateral root formation. Plant Mol Biol. 1999 Jan; 39(2):273-87. PMID: 10080694.
      View in: PubMed
    19. Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ, Eker AP, Hanaoka F, Bootsma D, Hoeijmakers JH. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell. 1998 Aug; 2(2):223-32. PMID: 9734359.
      View in: PubMed
    20. Sugasawa K, Ng JM, Masutani C, Maekawa T, Uchida A, van der Spek PJ, Eker AP, Rademakers S, Visser C, Aboussekhra A, Wood RD, Hanaoka F, Bootsma D, Hoeijmakers JH. Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity. Mol Cell Biol. 1997 Dec; 17(12):6924-31. PMID: 9372924.
      View in: PubMed
    21. Chiurazzi P, de Graaff E, Ng J, Verkerk AJ, Wolfson S, Fisch GS, Kozak L, Neri G, Oostra BA. No apparent involvement of the FMR1 gene in five patients with phenotypic manifestations of the fragile X syndrome. Am J Med Genet. 1994 Jul 15; 51(4):309-14. PMID: 7942992.
      View in: PubMed
    Ng's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description